Society for Immunotherapy of Cancer

Society for Immunotherapy of Cancer (SITC)
Formation 1984
Type Non-Profit Medical Society
Headquarters Milwaukee, WI
Official language
English
President
Francesco Marincola, MD, Sidra Medical and Research Center
Website www.sitcancer.org

The Society for Immunotherapy of Cancer (SITC), previously known as The International Society for Biological Therapy of Cancer (iSBTc) is a professional society of influential scientists, academicians, researchers, clinicians, government representatives, and industry leaders from around the world dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy. Currently, SITC has more than 600 members representing 17 medical specialties and are engaged in research and treatment of at least a dozen types of cancer.

Through emphasis on high-caliber scientific meetings, dedication to education and outreach activities, focus on initiatives of major importance to the field, and commitment to collaborations with like-minded organizations and patient advocacy groups, SITC brings together all aspects of the cancer immunology and immunotherapy community in an effort to make cancer immunotherapy one of the four standards of care and the word “cure” a reality for cancer patients living with this disease.

The goals of SITC are directed towards the rapid dissemination of information in these areas to expedite the safe transfer of both basic and applied research to the clinical setting.

Core Values

Interaction - Facilitate the exchange of information and education among basic and translational researchers, clinicians, young investigators, societies and groupssharing the mission of SITC

Innovation - Challenge the thinking and seek the best research in the development of cancer immunotherapy

Translation - Facilitate the transfer of cancer immunology and immunotherapy research from the bench to the clinic and back

Leadership - Define what is new and important and effectively communicate it to all relevant stakeholders [1]

Activities

SITC holds several programs each year with the purpose of gathering leaders to discuss the latest developments in cancer immunotherapy and biological therapy, and to focus on and educate the clinical and translational aspects of biologic approaches to cancer treatment. [2]

Membership

SITC's membership consists of over 800 leaders and up-and-coming scientists in the field of biological therapy. This group includes academicians, government representatives, industry leaders, senior investigators, and students. SITC’s members represent 17 medical specialties and are engaged in research and treatment of at least a dozen types of cancer.[3]

Publications

The Journal for ImmunoTherapy of Cancer (JITC) is the official journal of the Society for Immunotherapy of Cancer (SITC). It is an open access, online journal created by the Society for the many stakeholders in the tumor immunology and cancer immunotherapy community. JITC is an outlet and targeted publication platform dedicated to advancing the science of tumor immunology and cancer immunotherapy. [4]

References

  1. "Core Values". SITC - General Society. Retrieved 18 March 2013.
  2. "Meetings". SITC Meetings. Retrieved 18 March 2013.
  3. "General Society". General Society. Retrieved 18 March 2013.
  4. "JITC/SITC". About the Journal. Retrieved 18 March 2013.
This article is issued from Wikipedia - version of the Sunday, April 17, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.